These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 20950702)

  • 41. Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder.
    Kalra A; Roessner C; Jupp J; Williamson T; Tellier R; Chaudhry A; Khan F; Taparia M; Jimenez-Zepeda VH; Stewart DA; Daly A; Storek J
    Cytotherapy; 2018 May; 20(5):706-714. PubMed ID: 29580864
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
    Merlino C; Cavallo R; Bergallo M; Giacchino F; Bollero C; Negro Ponzi A; Cavallo G
    New Microbiol; 2003 Apr; 26(2):141-9. PubMed ID: 12737195
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
    Meijer E; Cornelissen JJ
    Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.
    Yang J; Tao Q; Flinn IW; Murray PG; Post LE; Ma H; Piantadosi S; Caligiuri MA; Ambinder RF
    Blood; 2000 Dec; 96(13):4055-63. PubMed ID: 11110673
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment.
    Juvonen E; Aalto SM; Tarkkanen J; Volin L; Mattila PS; Knuutila S; Ruutu T; Hedman K
    Bone Marrow Transplant; 2003 Jul; 32(1):97-102. PubMed ID: 12815484
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation.
    Cesaro S; Pegoraro A; Tridello G; Calore E; Pillon M; Varotto S; Abate D; Barzon L; Mengoli C; Carli M; Messina C
    Transplantation; 2010 Jun; 89(12):1533-40. PubMed ID: 20463647
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges.
    Kittan NA; Beier F; Kurz K; Niller HH; Egger L; Jilg W; Andreesen R; Holler E; Hildebrandt GC
    Transpl Infect Dis; 2011 Oct; 13(5):524-30. PubMed ID: 21395956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epstein-Barr virus (EBV) load in cerebrospinal fluid and peripheral blood of patients with EBV-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation.
    Liu QF; Ling YW; Fan ZP; Jiang QL; Sun J; Wu XL; Zhao J; Wei Q; Zhang Y; Yu GP; Wu MQ; Feng R
    Transpl Infect Dis; 2013 Aug; 15(4):379-92. PubMed ID: 23692640
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation.
    Delapierre B; Reman O; Dina J; Breuil C; Bellal M; Johnson-Ansah H; Gac AC; Damaj G; Chantepie S
    Curr Res Transl Med; 2019 Nov; 67(4):145-148. PubMed ID: 30871955
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes.
    Xu LP; Zhang CL; Mo XD; Zhang XH; Chen H; Han W; Chen YH; Wang Y; Yan CH; Wang JZ; Wang FR; Zhao T; Liu YR; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2185-2191. PubMed ID: 26253005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation.
    Bordon V; Padalko E; Benoit Y; Dhooge C; Laureys G
    Pediatr Transplant; 2012 Mar; 16(2):144-50. PubMed ID: 22288846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The efficacy and safety of rituximab in treatment of Epstein-Barr virus disease post allogeneic hematopoietic stem-cell transplantation].
    Xu LP; Liu DH; Liu KY; Zhang CL; Wang FR; Wang JZ; Wang Y; Chen H; Zhang YY; Yan CH; Han W; Chen YH; Zhao T; Zhang XH; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2012 Dec; 51(12):966-70. PubMed ID: 23327959
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children.
    Faraci M; Caviglia I; Morreale G; Lanino E; Cuzzubbo D; Giardino S; Di Marco E; Cirillo C; Scuderi F; Dallorso S; Terranova P; Moroni C; Castagnola E
    Bone Marrow Transplant; 2010 Jun; 45(6):1052-5. PubMed ID: 19855442
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation.
    Liu QF; Fan ZP; Luo XD; Sun J; Zhang Y; Ding YQ
    Transpl Infect Dis; 2010 Aug; 12(4):284-91. PubMed ID: 20345506
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
    Luo XY; Mo XD; Xu LP; Zhang XH; Wang Y; Liu KY; Chang YJ; Zhao XY; Huang XJ
    Ann Hematol; 2020 Nov; 99(11):2649-2657. PubMed ID: 32206854
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Epstein-Barr virus (EBV) infections in patients treated with allogenic hematopoietic cells transplantation (allo-HCT)].
    Zawilińska B; Piatkowska-Jakubas B; Kopeć J; Daszkiewicz E; Kleszcz E; Szostek S; Mensah-Glanowska P; Hawrylecka D; Skotnicki A
    Przegl Epidemiol; 2006; 60(1):87-92. PubMed ID: 16758744
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Surveillance of Epstein-Barr virus loads in adult liver transplantation: associations with age, sex, posttransplant times, and transplant indications.
    Schaffer K; Hassan J; Staines A; Coughlan S; Holder P; Tuite G; McCormick AP; Traynor O; Hall WW; Connell J
    Liver Transpl; 2011 Dec; 17(12):1420-6. PubMed ID: 21837744
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of EBV DNA in the cord blood donor for a patient developing Epstein-Barr virus-associated lymphoproliferative disorder following mismatched unrelated umbilical cord blood transplantation.
    Haut PR; Kovarik P; Shaw PH; Walterhouse D; Jenson HB; Kletzel M
    Bone Marrow Transplant; 2001 Apr; 27(7):761-5. PubMed ID: 11360119
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation.
    Gruhn B; Meerbach A; Häfer R; Zell R; Wutzler P; Zintl F
    Bone Marrow Transplant; 2003 Jun; 31(11):1023-5. PubMed ID: 12774054
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.